Bridging The Gap: Satisfying Payers In An Era of Expedited Regulatory Pathways

August 23, 2017

Regulatory approval has always been the main hurdle for developers trying to bring needed new drugs to patients. However, today, as expedited regulatory pathways enable drugs for severe diseases to be approved with less data, the gap has widened between what evidence regulators require and what payers desire to make their reimbursement decisions. Companies need to bridge the gap to ensure approvals are obtained from both regulators and payers so patients can get the treatments they need.

Previous Flipbook
The Opportunity And Pitfalls of Seeking Early Scientific Advance In The EU
The Opportunity And Pitfalls of Seeking Early Scientific Advance In The EU

While the advantages of seeking and adhering to the advice given by the EMA are clear, there are also sever...

Next Flipbook
Nothing Costs More Than Failure
Nothing Costs More Than Failure

Learn the top reasons drugs fail to be recommended for market access.